Literature DB >> 15163276

Pharmacological management of attention-deficit hyperactivity disorder.

Gloria Reeves1, Julie Schweitzer.   

Abstract

Pharmacotherapy is the most common intervention for attention-deficit hyperactivity disorder (ADHD). Stimulant medications are highly efficacious and are the gold-standard for treating the inattention, impulsivity and excessive motoric activity associated with ADHD. Methylphenidate and amphetamine-based stimulants are now available in longer-acting, once-daily and shorter-acting divided dosing schedules. Several nonstimulant, second-line treatments are now available or under development for the treatment of ADHD in children and adults. This article reviews the support for a variety of pharmacological agents and the issues to be considered when selecting an agent. The authors conclude that there is a need for additional direct comparisons between the longer-acting agents to effectively guide the practicing clinician.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163276     DOI: 10.1517/14656566.5.6.1313

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  9 in total

1.  Ningdong granule: a complementary and alternative therapy in the treatment of attention deficit/hyperactivity disorder.

Authors:  Ji-Jun Li; Zai-Wang Li; Shu-Zhen Wang; Fang-Hua Qi; Lin Zhao; Hong Lv; An-Yuan Li
Journal:  Psychopharmacology (Berl)       Date:  2011-03-18       Impact factor: 4.530

Review 2.  Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder.

Authors:  Vanessa R Anderson; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

3.  Methylphenidate increases cigarette smoking.

Authors:  Craig R Rush; Stephen T Higgins; Andrea R Vansickel; William W Stoops; Joshua A Lile; Paul E A Glaser
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

4.  The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement.

Authors:  S R Engel; T K Creson; Y Hao; Y Shen; S Maeng; T Nekrasova; G E Landreth; H K Manji; G Chen
Journal:  Mol Psychiatry       Date:  2008-01-29       Impact factor: 15.992

5.  Combination pharmacotherapy for adult ADHD.

Authors:  Lenard A Adler; Lisa S Reingold; Melinda S Morrill; Timothy E Wilens
Journal:  Curr Psychiatry Rep       Date:  2006-10       Impact factor: 8.081

6.  Reward-enhancing effects of d-amphetamine and its interactions with nicotine were greater in female rats and persisted across schedules of reinforcement.

Authors:  Kathleen R McNealy; Margaret E Ramsay; Scott T Barrett; Rick A Bevins
Journal:  Behav Pharmacol       Date:  2021-08-01       Impact factor: 2.277

7.  Personalized Medication Response Prediction for Attention-Deficit Hyperactivity Disorder: Learning in the Model Space vs. Learning in the Data Space.

Authors:  Hin K Wong; Paul A Tiffin; Michael J Chappell; Thomas E Nichols; Patrick R Welsh; Orla M Doyle; Boryana C Lopez-Kolkovska; Sarah K Inglis; David Coghill; Yuan Shen; Peter Tiño
Journal:  Front Physiol       Date:  2017-04-11       Impact factor: 4.566

8.  A pharmacological analysis of stimulant-induced increases in smoking.

Authors:  Andrea R Vansickel; William W Stoops; Paul E A Glaser; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2007-04-20       Impact factor: 4.415

9.  Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine.

Authors:  Alain Joseph; Martin Cloutier; Annie Guérin; Roy Nitulescu; Vanja Sikirica
Journal:  Patient Prefer Adherence       Date:  2016-03-24       Impact factor: 2.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.